Register Today for Agena Bioscience’s PGx Workshop

Wednesday, November 6, 2019

Pharmacogenetic (PGx) Sample Mischaracterization: The Prevalence and Impact of CYP2D6 Hybrid Alleles

Downtown Baltimore9:00 am – 9:50 am
Room #337
Baltimore Convention Center

Guest Speakers:

  • Houda Hachad, Pharm.D, Chief Scientific Officer, Translational Software

  • Carissa Wachtler, MB(ASCP)CM, Chief Technology Officer/VP Research and Development, AccessDx

  • Darryl Irwin, PhD, Senior Director, Scientific Affairs, Agena Bioscience

CYP2D6 is one of the most important pharmacogenetic genes, being responsible for the metabolism and elimination of approximately 25% of clinically used drugs. It’s estimated that up to 45% of individuals possess a non-functional CYP2D6 hybrid allele. Common CYP2D6 genotyping and copy number variation detection methods cannot detect these alleles, resulting in pharmacogenetic profile mischaracterization. This session will provide an overview of CYP2D6 hybrid alleles, share studies showing their prevalence across populations, and discuss the genetic characteristics that make their detection difficult. PGx experts will offer pragmatic recommendations for overcoming this unique challenge to provide a comprehensive CYP2D6 pharmacogenetic profile. 

If you’re unable to attend, we encourage you to register and provide your email as we will follow-up with the workshop recording and supplemental materials.


About Agena Bioscience

Agena Bioscience enables clinical laboratories world-wide to deliver affordable targeted genomic testing. Our team will be at AMP 2019, and we’re excited to engage in dialogue with you!


With exception of the MassARRAY® Dx, all other products are For Research Use Only. Not for use in diagnostic procedures.

Register Now